Otsuka Pakistan Limited (PSX: OTSU)

Market Cap	2.27B
Revenue (ttm)	3.18B
Net Income (ttm)	-160.37M
Shares Out	12.10M
EPS (ttm)	-13.25
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,560
Average Volume	21,767
Open	190.12
Previous Close	192.39
Day's Range	184.56 - 190.13
52-Week Range	105.05 - 209.12
Beta	0.27
RSI	54.36
Earnings Date	Feb 17, 2025

About Otsuka Pakistan

Otsuka Pakistan Limited manufactures, markets, and distributes intravenous infusions in Pakistan and Afghanistan. The company offers intravenous solutions, including electrolyte and standard solutions, ampoules, OTSUZOL, and ciprofloxacin and OTSUMOL infusion products; medical devices, such as urea breath test systems, plasline solutions, sirolimus eluting coronary stent system, eucaLIMUS, and eucaVI; clinical nutrition products comprising aminoleban oral, aminovel 600, pan-amin G, aminoleban injection, and proten gold; and therapeutic drugs, w...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 345
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: OTSU

Financial Performance

In 2024, Otsuka Pakistan's revenue was 3.16 billion, an increase of 4.24% compared to the previous year's 3.04 billion. Losses were -4.76 million, -33.91% less than in 2023.